The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,100 and keeps an Overweight rating on the shares. The firm ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...

Learn more about whether Alvotech or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, ...

The company has successfully developed several blockbuster medicines, including Eylea and Eylea HD for retinal diseases (such as wet age-related macular degeneration, diabetic macular edema ...

Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8, after the company announced that its ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...